Skip to main content
Midas Edge

NEOGENOMICS INC

For the period ended Jun 30, 2025. Filed Jul 29, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 29, 2025

NEO$17.60+4.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

Exhibit NumberDescription of ExhibitLocation
3.1Articles of Incorporation, as amendedIncorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 28, 2020 (File No. 001-35756).
3.2Amended and Restated Bylaws, as amendedIncorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, as filed with the SEC on November 6, 2015 (File No. 001-35756).
3.3Amendment to the Amended and Restated Bylaws of NeoGenomics, Inc.Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the SEC on April 8, 2025 (File No. 001-35756).
10.1Employment Agreement effective April 1, 2025, by and between NeoGenomics, Inc. and Anthony Zook.Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the SEC on March 31, 2025 (File No. 001-35756).
10.2Special Advisor Agreement between NeoGenomics, Inc. and Christopher Smith, effective April 1, 2025.Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the SEC on January 10, 2025 (File No. 001-35756).
10.3Separation Agreement, dated as of April 27, 2025, between NeoGenomics Inc. and Melody Harris.Incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as filed with the SEC on April 29, 2025 (File No. 001-35756).
10.4First Amendment of the NeoGenomics, Inc. 2023 Equity Incentive Plan, as approved by the Company's stockholders on May 22, 2025Incorporated by reference to Annex A of the Company'sProxy Statement on Form DEF 14A as filed with theSEC on April 8, 2025 (File No. 001-35756).
31.1Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Provided herewith.
31.2Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Provided herewith.
32.1Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Provided herewith.
101.INSXBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)Provided herewith.
101.SCHXBRL Taxonomy Extension Schema DocumentProvided herewith.
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentProvided herewith.
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentProvided herewith.
101.LABXBRL Taxonomy Extension Labels Linkbase DocumentProvided herewith.
101.PREXBRL Taxonomy Extension Presentation Linkbase DocumentProvided herewith.
104Cover Page Interactive File (formatted as inline XBRL and contained within Exhibit 101)Provided herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.